–>
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a leading global medical provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, announced the proposed issuance of shares and the issuance of stock options.
Under shares for debt agreements, the Company will issue an aggregate of 650,000 common shares of the Company (“Shares”) to directors of the Company at a deemed price of $0.05 per Share. The Shares will be provided to settle debt for service expenses and will be subject to a four month hold period in accordance with applicable securities laws.
The Company also granted 62,500 stock options to a director of the Company, each option exercisable at $0.05 per Share for five years from the date of grant and vesting immediately. The options are subject to the provisions of the Company’s Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws. The Company also announces the final tranche of shares to AGORA Internet Relations Corp. (“AGORACOM”) in the amount of 226,000 Shares, representing a price of $0.05 per Share, for services valued at $10,000 plus 13% HST. AGORA is an online marketing and awareness company that will extend its support and coverage of CardioComm Solutions into the current calendar year, at no additional cost to the Company. Agoracom’s market coverage will complement CardioComm’s 2020 marketing campaign efforts for the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app. The campaign will highlight the availability of rapid ECG reading services through the Company’s SMART Monitoring ECG reading fee-for-service and connectivity readiness of this solution to hospitals where the Company’s GEMS™ software is licensed.
To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at
www.cardiocommsolutions.com and www.theheartcheck.com.
